Noradrenalin Kabi (Noradrenaline Tartrate)

Noradrenaline Tartrate, the active ingredient in Noradrenalin Kabi, is a sympathomimetic presented as an injection solution for intravenous use. It is employed to raise blood pressure in patients experiencing acute hypotension, septic shock, cardiac arrest, or postoperative hypotension, typically in intensive care or emergency settings.

GNH USA supplies Noradrenalin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to European Union quality standards and provides regulatory documentation for global distribution.

Noradrenalin Kabi, a vasopressor acting on the sympathetic nervous system, is used in critical care settings to rapidly increase vascular tone and cardiac output, thereby managing severe hypotension. - Acute hypotension: restores arterial pressure to ensure adequate organ perfusion in shock states. - Septic shock: supports circulatory function when fluid resuscitation alone is insufficient. - Cardiac arrest: provides temporary pressor support during advanced cardiac life support. - Postoperative hypotension: stabilizes hemodynamics after surgery to prevent organ ischemia. - Other severe hypotensive states: used when conventional therapies fail to maintain target blood pressure.

Noradrenalin Kabi may be associated with a range of adverse reactions, varying from mild to life‑threatening.

Common Side Effects: - Tachycardia: increased heart rate due to β1 stimulation. - Hypertension: excessive rise in blood pressure from α1 vasoconstriction. - Arrhythmia: irregular cardiac rhythm, especially in predisposed patients. - Peripheral ischemia: reduced blood flow to extremities causing pain or discoloration. - Headache: vascular changes leading to cranial discomfort. - Nausea: gastrointestinal upset.

Serious or Rare Side Effects: - Myocardial ischemia: reduced coronary perfusion leading to chest pain or infarction. - Severe arrhythmias: ventricular tachycardia or fibrillation requiring immediate intervention. - Tissue necrosis at infusion site: extravasation causing local tissue damage. - Pulmonary edema: fluid accumulation in lungs due to increased afterload. - Anaphylaxis: rare hypersensitivity reaction with airway compromise.

When using Noradrenalin Kabi, careful monitoring and specific precautions are essential to ensure patient safety. - Cardiovascular monitoring: continuous blood pressure and heart‑rate observation during infusion. - Dosage titration: adjust infusion rate based on real‑time hemodynamic response. - Electrolyte balance: monitor serum potassium and calcium levels regularly. - Contraindications: avoid use in patients with known hypersensitivity to noradrenaline. - Interaction with MAO inhibitors: discontinue MAO inhibitors at least 24 hours before therapy. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Noradrenalin Kabi can interact with several medications, altering its pressor effect or increasing risk of adverse events.

Major Interactions (Avoid): - MAO inhibitors: may cause hypertensive crisis when combined. - Tricyclic antidepressants: synergistic pressor effect leading to severe hypertension. - Beta‑blockers: can blunt the intended increase in heart rate and contractility.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance hypotensive episodes if noradrenaline dose is reduced. - Diuretics: can affect intravascular volume, requiring careful dose adjustment. - Calcium channel blockers: may potentiate vasodilatory effects, necessitating monitoring. - Other vasopressors: concurrent use may lead to excessive vasoconstriction.